Osaterone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584964

CAS#: 105149-04-0

Description: Osaterone is effective against prostatic hyperplasia in dogs.


Chemical Structure

img
Osaterone
CAS# 105149-04-0

Theoretical Analysis

MedKoo Cat#: 584964
Name: Osaterone
CAS#: 105149-04-0
Chemical Formula: C20H25ClO4
Exact Mass: 364.14
Molecular Weight: 364.866
Elemental Analysis: C, 65.84; H, 6.91; Cl, 9.72; O, 17.54

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 105149-04-0   105149-00-6 (acetate)  

Synonym: Osaterone

IUPAC/Chemical Name: ( )-6-Chloro-17-hydroxy-2-oxapregna-4,6-diene-3,20-dione

InChi Key: ZLLOIFNEEWYATC-XMUHMHRVSA-N

InChi Code: InChI=1S/C20H25ClO4/c1-11(22)20(24)7-5-14-12-8-16(21)15-9-17(23)25-10-18(15,2)13(12)4-6-19(14,20)3/h8-9,12-14,24H,4-7,10H2,1-3H3/t12-,13+,14+,18-,19+,20+/m1/s1

SMILES Code: CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])C=C(Cl)C4=CC(OC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 364.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Albouy M, Sanquer A, Maynard L, Eun HM. Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs. Vet Rec. 2008 Aug 9;163(6):179-83. PubMed PMID: 18689779.

2: Tsutsu T, Hori T, Shimizu M, Orima H, Kawakami E, Fukuda S. Regression of prostatic hypertrophy by osaterone acetate in dogs. J Vet Med Sci. 2000 Oct;62(10):1115-9. PubMed PMID: 11073087.

3: Socha P, Zduńczyk S, Tobolski D, Janowski T. The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia. Pol J Vet Sci. 2018 Dec;21(4):559-566. doi: 10.24425/pjvs.2018.125601. PubMed PMID: 30605276.

4: Tsutsui T, Hori T, Shimizu M, Tatsuzawa C, Kawakami E. Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen quality in dogs with benign prostatic hypertrophy. J Vet Med Sci. 2001 Apr;63(4):453-6. PubMed PMID: 11346183.

5: Niżański W, Levy X, Ochota M, Pasikowska J. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update. Reprod Domest Anim. 2014 Jun;49 Suppl 2:8-15. doi: 10.1111/rda.12297. Review. PubMed PMID: 24947855.

6: Minato K, Koizumi N, Honma S, Tsukamoto K, Iwamura S. Pharmacokinetics and biliary excretion of osaterone acetate, a new steroidal antiandrogen, in dogs. Drug Metab Dispos. 2002 Feb;30(2):167-72. PubMed PMID: 11792686.

7: Minato K, Honma S, Shinohara Y, Hashimoto T. Metabolism of osaterone acetate in dogs and humans. Steroids. 2005 Aug;70(9):563-72. PubMed PMID: 15923016.

8: Fuse H, Fukumoto S, Sone H, Miyata Y, Saito T, Nakayama K, Takahashi H, Matsumoto T, Ogata E. A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. J Bone Miner Res. 1997 Apr;12(4):590-7. PubMed PMID: 9101370.

9: Minato K, Koizumi N, Honma S, Iwamura S, Tsukamoto K. Characterizations of mouse hepatic microsomal monooxygenase catalyzing 11beta-hydroxylation of osaterone acetate. Biochem Pharmacol. 1999 Jul 15;58(2):335-41. PubMed PMID: 10423176.

10: Barbon AR, Ordóñez IA, Haworth P, Glendewar G, Routh A, Pocknell A. DIAGNOSIS AND MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA IN A PIED TAMARIN (SAGUINUS BICOLOR). J Zoo Wildl Med. 2016 Jun;47(2):609-13. doi: 10.1638/2015-0215.1. PubMed PMID: 27468035.